D espite numerous improvements in therapeutic options, heart failure (HF) is still the leading cause of death worldwide, indicating the need for an in-depth understanding of its cause and the development of innovative treatment strategies.
factors and humoral factors in addition to extracellular matrix proteins, and these factors are essential for pathological cardiac hypertrophy and also for normal heart development. 5, [17] [18] [19] When the myocardium is exposed to pathological conditions, such as pressure overload, CFs are activated and proliferate rapidly. Recently, it has been reported that the functions of CFs during cardiac remodeling have both adaptive and detrimental sides. 20, 21 Activated CFs promote pathological remodeling, and at the same time, CFs play essential roles in the adaptive response to pathological stimuli.
MicroRNAs (miRs) constitute a class of small noncoding RNAs that inhibit protein expression by base pairing to complementary sequences located within the 3′ untranslated region of target mRNAs. A highly conserved miR, miR-33, is considered a potential therapeutic target for atherosclerosis because recent reports, including ours, [22] [23] [24] [25] indicated that miR-33 has atherogenic effects by reducing high-density lipoprotein cholesterol (HDL-C) levels. 22, 23, 26, 27 MiR-33 (or miR-33a in primates) is encoded by intron 16 of sterol regulatory element-binding factor 2 (SREBF2), a master regulator of sterol and fatty acid synthesis, and suppresses genes involved in cholesterol metabolism, such as ABCA1 and ABCG1 (ATP-binding cassette transporter A1 and G1) as target genes (primates including Homo sapiens also have miR-33b in the intron of SREBF1 in addition to miR-33a 28 ). It was also reported that miR-33 is involved in inflammatory processes in atherosclerotic lesions 29 and fibrotic responses in the liver. 30 However, the functions of miR-33 in cardiac hypertrophy and heart failure, which are also chronic inflammatory and fibrotic processes as mentioned above, remain to be elucidated. MiR-33 is expressed ubiquitously, but its expression level in the heart varies depending on the report in question and varies from 0.5-to 10-fold of its expression in the liver. 22, 26, 27 MiR-33 can, at least, be detected in the heart at a similar level to that in the liver or in immune cells, which have been investigated intensively. However, there are no reports regarding the function of miR-33 in the heart.
In the present study, we investigated the functions of miR-33 in the remodeling heart using clinical samples and genetic mouse models. We first investigated the correlation between expression levels of miR-33a/b in myocardial biopsy samples and hemodynamic parameters in patients with dilated cardiomyopathy. Next, we used miR-33-deficient (knockout [KO]) mice (both whole body KO and fibroblast-specific KO) to examine the role of miR-33 in cardiac hypertrophy and fibrosis. We applied transverse aortic constriction (TAC), a model of left ventricular pressure overload characterized by cardiac myocyte hypertrophy and interstitial fibrosis.
Methods
Detailed Methods are provided in the Online Data Supplement.
Myocardial Biopsy
We analyzed the expression levels of miR-33a/b in the tissues of endomyocardial biopsies from left ventricles (LVs) and examined the relationship between their expression levels and hemodynamic parameters in 33 patients who were diagnosed with dilated cardiomyopathy at Osaka Red Cross Hospital. 31 Hemodynamic parameters were obtained by catheterization. 
Novelty and Significance
What Is Known?
• Multiple processes, such as myocyte hypertrophy, immune cell activation, and fibrosis, are involved in heart failure.
• MicroRNAs play critical roles in heart failure by fine-tuning gene expression.
• MicroRNA-33 (miR-33) regulates lipid metabolism and inflammation.
What New Information Does This Article Contribute?
• MiR-33 is involved in cardiac remodeling, especially in cardiac fibrosis.
• MiR-33 regulates fibroblast proliferation by maintaining lipid raft cholesterol content.
Chronic inflammation followed by fibrosis is an important underlying mechanism of heart failure. The similar processes can be seen in other disorders, including atherosclerosis. Inhibition of miR-33 is a potent therapeutic strategy for atherosclerosis because miR-33 reduces high-density lipoprotein cholesterol levels and promotes chronic inflammation. However, the role of miR-33 in the heart is unknown. Here, we showed that miR-33 was involved even in cardiac remodeling, especially in fibrosis, using human samples and genetic mouse models. In human samples, the expression of miR-33 was downregulated in high-stage heart failure patients. In the mouse models, deficiency of miR-33 reduced cardiac fibrosis but worsened systolic function after pressure overload in vivo. Deficiency of miR-33 impaired fibroblast proliferation because of decreased lipid raft cholesterol in vitro. Our data showed new roles of miR-33 in cardiac remodeling and fibroblast proliferation. This study is notable, in that it showed the relationship between cellular lipid homeostasis and fibrotic responses. This study also implicated the possibility of pleiotropic effects of miR-33 inhibition, regardless of protective or harmful effects, because it may modulate lipid rafts. It will be necessary to consider these effects to translate the silencing of miR-33 to humans.
informed consent for the procedure and gene expression analyses. The ethics committee of Osaka Red Cross Hospital approved the study protocol.
Mice
MiR-33 KO mice were generated as reported previously. 22 MiR-33-floxed mice were generated by homologous recombination in a C57BL/6J background as described in the Online Data Supplement. 32 Pn-Cre (Periostin-Cre) mice were generated by Dr Conway and colleagues. 21, 33 Mice were maintained in specific pathogen-free conditions at the Institute of Laboratory Animals of Kyoto University Graduate School of Medicine. This study was approved by the Kyoto University Ethics Review Board. The primer sequences for genotyping are listed in Online Table II . All the in vivo experiments were performed using male mice in a C57BL/6J background.
Pressure Overload Model
TAC was performed as described previously.
34-36

Primary Neonatal Rat Cardiac Myocytes and Fibroblasts
Neonatal rat cardiac myocytes and CFs were isolated from 1-dayold Sprague-Dawley rats, as described previously. 36 After enzymatic digestion with pancreatin (Sigma, P3292), cardiac myocytes and fibroblasts were purified by Percoll density gradient centrifugation (Sigma, P4937).
Culture of Fibroblasts
For isolation of adult CFs, hearts from 8-week-old mice were digested with collagenase/dispase solution (Roche, 11097113001) and plated for 2 hours. 18 We used adult CFs at passage 3 to 4. For isolation of tail-tip fibroblasts, the tails from 8-week-old mice were peeled, minced into 1 cm pieces, placed on gelatin-coated culture dishes, and incubated for 5 days. 37 Cells that migrated out of the graft pieces were transferred to new plates (passage 1). We used tail-tip fibroblasts at passage 4 to 5. Mouse embryonic fibroblasts were isolated from wildtype (WT) and miR-33KO embryos at E14.5. We used mouse embryonic fibroblasts at passage 5 to 6.
Quantitative Real-Time PCR
To evaluate mRNA expression, single-strand cDNA was synthesized from 1 µg of total RNA by means of reverse transcriptase reaction and quantitative polymerase chain reaction (PCR) was performed using a LightCycler 96 (Roche Diagnostics) with THUNDERBIRD SYBR qPCR Mix (TOYOBO, QPS-201). Expression levels were normalized by housekeeping genes as indicated. The primer sequences are listed in Online Table III .
Quantitative Real-Time PCR for miR
Expression levels of miR-33a and miR-33b were measured using TaqMan MicroRNA Assays (Applied Biosystems) and a StepOnePlus Real-Time PCR System (Applied Biosystems) in accordance with the manufacturer's protocol. Expression levels of miRs were normalized by U6 small nuclear RNA and calculated by the 2 −ΔΔCt method.
Lipid Raft Staining
We used fluorescence-conjugated cholera toxin subunit B (CTB) for lipid raft labeling. To obtain images of lipid raft staining, fibroblasts were plated onto chamber slides and stained with Vybrant Alexa Fluor 594 Lipid Raft Labeling Kit (Molecular Probes, V34405). To quantify the signals from CTB-labeled lipid rafts on the cell surface, flow cytometric analyses were performed. Fibroblasts were plated on 10-cm culture dishes and cultured overnight. The cells were dissociated using trypsin EDTA, and stained with 1 μg/mL fluorescein isothiocyanate-conjugated CTB (Sigma, C1655) at 4°C for 15 minutes and then analyzed on a FACSAriaII (Becton Dickinson). To make control samples with decreased lipid rafts, some samples were incubated with 5 mmol/L methyl-β-cyclodextrin for 1 hour before labeling with CTB.
Echocardiography
To analyze the cardiac function of mice, we performed echocardiography (Vevo 2100, VisualSonics) at the indicated time points after TAC.
Statistical Analysis
Measurements except for clinical biopsy data are presented as means±SEM. Measurements for clinical samples are presented as median±interquartile range or mean±SD as indicated. To compare gene expression levels and the hemodynamic parameters in Figure 1A , linear regression analysis was performed using R version 3.2.3 (The R Project). For Gene Ontology analysis, the clusterProfiler package in R/Bioconductor was used for data sets with differentially expressed genes. P values were adjusted by false discovery rate correction. For other statistical comparisons, unpaired Student t test (2 groups, parametric), Mann-Whitney test (2 groups, nonparametric), or 1-way ANOVA with Sidak post hoc test (3 or more groups) were used as indicated in the figure legends. A P value of <0.05 was considered as statistically significant. Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc).
Results
MiRNA-33a expression levels in cardiac tissue are associated with improving hemodynamic parameters in patients with dilated cardiomyopathy.
To analyze the expression pattern of miR-33a/b in human remodeling hearts, we measured their levels using TaqMan quantitative PCR in the tissues from endomyocardial biopsies of LVs and examined the relationships between miR-33a/b expression levels and hemodynamic parameters obtained by catheterization in patients with dilated cardiomyopathy.
A total of 33 patients were included in the analysis (Online Table I ). The cardiac expression level of miR-33a was modestly but significantly correlated with ejection fraction (EF) and inversely correlated with pulmonary capillary wedge pressure, whereas the expression level of miR-33b was not correlated with these parameters ( Figure 1A ). Thus, we focused on miR33a, which is highly conserved across species unlike miR-33b.
When the patients were categorized by Forrester classification (there were no patients with Forrester II HF in this cohort; Online Table I) , miR-33a expression levels in patients with high-stage HF (Forrester III or IV) were significantly lower than its expression in patients with low-stage HF (Forrester I; Figure 1B ), whereas the expression of SREBF2, whose intron 16 has the coding region of miR-33a, did not differ among the groups ( Figure 1C ).
These data from the clinical samples indicated that decreased miR-33a was associated with worsened cardiac function and miR-33a had function in the development of HF.
MiRNA-33 plays an important role in pressure overloadinduced cardiac fibrosis.
Because rodents have only miR-33a, but not miR-33b, unlike human or nonhuman primates, miR-33KO mice are good tool to analyze miR-33a functions. As we previously reported, miR-33KO mice show normal growth and displayed no obvious abnormalities in heart development. 22 To analyze the function of miR-33 in response to pathological stimuli, mice were subjected to pressure overload-induced cardiac hypertrophy by TAC.
To analyze hypertrophic and fibrotic responses to TAC, we performed gene expression analyses in sham-or TAC-operated WT and miR-33KO LVs at 2 weeks after operation and also histological analyses at 4 weeks after operation. The expression level of miR-33 was significantly upregulated in response to TAC in WT LVs (Figure 2A ). Heart weight and cardiac myocyte size were increased similarly in WT and miR-33KO mice after TAC ( However, histological analysis showed that TACinduced cardiac fibrosis was ameliorated in miR-33KO mice ( Figure 2D and 2E). Moreover, TAC-induced upregulation of fibrosis-related genes, such as Col1a1, Postn, and Tgfb3 in LVs, was significantly suppressed in miR-33KO mice compared with WT mice, despite the similar expression level of a hypertrophic marker, Nppb ( Figure 2F ).
To analyze gene expression more comprehensively, we performed microarray analysis. The microarray data detected 114 upregulated genes and 148 downregulated genes in miR-33KO hearts versus WT hearts after TAC (fold change >2). Gene ontology analysis using the downregulated genes showed that several biological processes related to fibrosis and extracellular matrix were enriched (Online Figure II) . The heatmap data showed suppressed upregulation of fibrosis-related genes by TAC in miR-33KO mice (Online Figure  III; orange cluster in A, red and orange cluster in C, and red cluster in D), whereas the genes involved in cardiac muscle contraction showed only small changes (Online Figure IIIB) .
These data showed that miR-33 deficiency did not affect the hypertrophic response to TAC but alleviated the fibrotic response to TAC. Therefore, miR-33 was considered to play an important role in TAC-induced cardiac fibrosis.
Deficiency of miR-33 worsened systolic function after chronic pressure overload.
As shown above, miR-33 deficiency alleviated fibrotic response in the heart after TAC. To investigate whether the alterations by miR-33 deficiency improved cardiac function in vivo, we performed echocardiography of WT and miR-33KO mice ≤8 weeks after TAC. During the follow-up, no WT mice died, and only 1 miR-33KO mouse died at 8 weeks to increase in WT mice ( Figure 3D ). To analyze LV function more precisely, we measured global longitudinal strain and longitudinal strain rate using speckle-tracking strain imaging ( Figure 3F and Online Figure V) . We found that global longitudinal strain, a sensitive parameter for systolic function, also deteriorated in miR-33KO mice at 8 weeks after TAC. There were no significant differences in early diastolic longitudinal strain rate, a parameter for diastolic function.
In addition, the activation of protein kinase B (Akt), which is known to be protective in the remodeling heart, 38,39 was inhibited in miR-33KO LVs (Figure 3G and 3H) .
These data showed that deficiency of miR-33 deteriorated systolic function after chronic pressure overload, which was consistent with the human sample data shown in Figure 1 .
CFs are responsible for miR-33 expression in the heart, and miR-33-deficient fibroblasts have impaired proliferative capacity.
To clarify which cell type is the source of miR-33, we measured the expression level of miR-33 in Percoll-isolated neonatal rat cardiac myocytes and fibroblasts. The expression level of miR-33 in CFs was ≈3.4-fold higher than cardiac myocytes ( Figure 4A ; Online Figure VI) . Thus, CFs were considered to be responsible for miR-33 in the heart, which was consistent with the difference between the hypertrophic response and fibrotic response after TAC in miR-33KO mice as shown in Figure 2 .
Therefore, we focused on the function of miR-33 in fibroblasts. We isolated 3 types of fibroblasts from miR-33KO and control (WT) mice. Because proliferation and increased density of CFs are involved in cardiac fibrosis during pathological remodeling, 15, 20 we analyzed proliferative capacity of miR-33KO fibroblasts. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays showed that all the 3 types of miR-33KO fibroblasts had impaired proliferative capacity in vitro compared with WT fibroblasts ( Figure 4B ). Moreover, flow cytometric analysis showed impaired antiapoptotic capacity in miR-33KO fibroblasts against hydrogen peroxide ( Figure 4C and 4D) . MiR-33KO fibroblasts also showed impaired activation of Akt when stimulated with fetal bovine serum ( Figure 4G and 4H) . This was consistent with the impaired proliferation of miR-33 KO fibroblasts because Akt is one of the most important protein kinases that regulate cellular proliferation and survival. 40 To analyze cell proliferation in vivo, bromodeoxyuridine (BrdU) incorporation analysis was performed. Because CFs proliferate rapidly immediately after TAC, we analyzed BrdU incorporation in LVs on day 7 after TAC. By using confocal microscopy, we found that all the BrdU + cells were also positive for vimentin, and we could not detect any BrdU + cardiac myocytes in LVs. The number of vimentin + CFs positive for BrdU after 7-day TAC was significantly smaller in miR-33KO LVs than WT ( Figure 4E and 4F) . It confirmed impaired proliferative capacity of miR-33KO fibroblasts in vivo.
Taken together, miR-33 was considered to be necessary to maintain appropriate proliferation of fibroblasts in vitro and also in vivo.
Deficiency of miR-33 increased the expression level of ABCA1 and decreased lipid raft content in CFs.
Recent studies have shown that miR-33 has atherogenic and proinflammatory effects because it regulates cholesterol metabolism in the liver and immune cells via inhibition of genes involved in cholesterol efflux and transport, such as ABCA1, ABCG1, and NPC1 (Niemann-Pick C1). 22, 23, 29, 30, 41 Among these genes, we confirmed the upregulation of ABCA1 even in miR-33KO CFs ( Figure 5A and Online Figure VIIA-VIIC) .
Because of the altered proliferative capacity and altered gene expression involved in cholesterol metabolism in miR-33KO fibroblasts, we speculated that altered lipid rafts in miR-33KO fibroblasts were the underlying mechanism of the reduced fibrosis of miR-33KO hearts. To analyze lipid raft content in miR-33KO fibroblasts, we stained lipid rafts by fluorescence-conjugated CTB, which binds to ganglioside GM1 on the plasma membrane and is a marker to identify lipid rafts. Analyses by confocal laser scanning microscopy showed reduced lipid raft content in miR-33KO fibroblasts compared with WT fibroblasts ( Figure 5B ). To quantify the signal intensity by CTB binding that marked lipid rafts, we used flow cytometry. The mean fluorescence intensity of miR-33KO fibroblasts marked by fluorescein isothiocyanate-CTB was significantly lower than that of WT fibroblasts ( Figure 5C and 5D). The altered lipid rafts in miR-33KO fibroblasts were consistent with the impaired activation of Akt because it has been reported that lipid rafts are involved in the phosphatidylinositol-3 kinase/Akt signaling pathway and that Akt is phosphorylated in lipid rafts on the plasma membrane ( Figure 4G and 4H) . 42, 43 To investigate whether ABCA1 is involved in the impaired proliferation of miR-33KO fibroblasts, we performed siRNA-mediated knockdown of ABCA1. Both WT and miR-33KO fibroblasts showed similar proliferation in the condition of siRNA-mediated knockdown of ABCA1 ( Figure 5E and Online Figure VIID) . The results indicated that both ABCA1 and miR-33 are involved in cellular proliferation.
These data indicated that miR-33 maintained lipid raft content by regulating genes involved in cholesterol metabolism.
CF-specific deletion of miR-33 ameliorated cardiac fibrosis after pressure overload.
To eliminate the effect of increased HDL-C and the altered phenotype of immune cells in miR-33KO mice, we decided to analyze fibrotic responses in CF-specific miR-33-deficient mice. We generated miR-33-floxed mice, in which loxP sites flanked the pre-miR sequence of miR-33 (Online Figure  VIIIA-VIIID) . We confirmed that the expression of miR-33 was hardly detected in miR-33-deleted mice after crossing with Ayu1-Cre mice, which express Cre recombinase ubiquitously (Online Figure IXA) , and also that the expression and splicing of Srebf2 mRNA was not altered in both miR-33-floxed mice and miR-33-deleted mice (Online Figure IXB  and IXC) .
To generate CF-specific knockout mice, we used a transgenic mouse line in which Cre recombinase was driven by a 3.9-kb promoter of mouse Periostin (Pn-Cre), which is not normally expressed in adult hearts but induced specifically in CFs by pathological stimuli, such as pressure overload. Figure 6A ). The cell type in which the expression of miR-33 increased after TAC was thought to be CFs because the expression levels of miR-33 in FBKO mice were the same as at baseline (Figures 2A and 6A) . FBKO mice did not show higher HDL-C levels than littermate controls, whereas miR-33Δ / Δ mice showed higher HDL-C levels than control mice (Online Figure XA and XB) . This result suggested that miR-33 in fibroblasts did not contribute to HDL-C elevation.
Heart weight after TAC did not differ among FBKO and control mice ( Figure 6B ), whereas histological analysis showed that the fibrotic area of FBKO LVs was smaller than control mice ( Figure 6C and 6D) , like whole body KO mice. Gene expression analysis showed that fibrosis-related genes tended to be downregulated in FBKO LVs (Online Figure  XC) . Furthermore, FBKO mice showed smaller numbers of Ki-67-positive fibroblasts at 2 weeks after TAC (Figure 6E . WT or miR-33KO CFs cultured on 6-well plates were serum-starved for 2 hours and stimulated with 3% fetal bovine serum (FBS) for 3 minutes. H, Densitometry of p-Akt in CFs stimulated with FBS in G (n=12). Expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. *P<0.05, by unpaired 2-tailed Student t test. Data are presented as mean±SEM. DAPI indicates 4',6-diamidino-2-phenylindole. and 6F). Therefore, miR-33 was considered to contribute to CF proliferation and fibrotic responses after pathological stimuli, such as pressure overload.
Discussion
Here, by using genetic models, we demonstrate that deficiency of miR-33 resulted in reduced fibrotic response to pressure overload in vivo. Despite the reduction in fibrosis, cardiac function deteriorated in miR-33KO hearts. We also found that miR-33 in the heart was predominantly expressed in CFs, and deficiency of miR-33 impaired cell proliferation in fibroblasts both in vitro and in vivo, and that miR-33 preserved lipid raft cholesterol content in fibroblasts by regulating genes involved in cholesterol metabolism. Moreover, in clinical samples, miR-33a expression correlated with improving hemodynamic parameters, including EF. These data indicate that miR-33 promotes fibrotic responses in the heart by maintaining lipid raft content in fibroblasts, and the response has protective effects on cardiac function (Online Figure XIII) .
It has been said that miRs play critical roles in normal heart development and also in HF by fine-tuning gene expression because cardiac-specific deletion of Dicer, a gene that is essential for miR processing, leads to poorly developed myocardium, rapidly progressive HF, and postnatal lethality. [44] [45] [46] In our clinical samples, miR-33a expression was correlated with EF and inversely with mean pulmonary capillary wedge pressure, and its expression was downregulated in high-stage HF patients compared with low-stage HF patients. The results were consistent with our echocardiographic data using miR-33KO mice because EF and fractional shortening were significantly lower in miR-33KO mice compared with WT mice after chronic pressure overload. The wall thickness stopped increasing at 4 to 8 weeks after TAC in miR-33KO mice, and this indicated insufficient hypertrophic adaptation. In addition, the upregulation of miR-33 after TAC was only in the early phase (Online Figure IE) . These data indicated that miR-33 had protective effects on developing HF.
MiR-33a (or miR-33 in rodents) is transcribed from intron 16 of SREBF2, which is a master regulator of lipid synthesis. 22 Expression of SREBF2 mRNA did not differ between lowstage HF patients and high-stage HF patients, whereas expression of miR-33a was different between the groups. It seemed that this was because of post-transcriptional regulation of miR-33a, such as processing by DROSHA and DICER.
Next, gene expression and histological analyses using miR-33KO mice after TAC showed that deficiency of miR-33 did not affect hypertrophic responses but alleviated fibrotic responses to pressure overload. We also found that the expression of miR-33 was predominant in CFs. Moreover, the phenotype of the reduced fibrotic response was also reproduced in CF-specific miR-33-deficient mice. These data were consistent with recent reports that inhibition of miR-33 reduces liver fibrosis in a nonalcoholic steatohepatitis model and that expression of miR-33 in hepatic stellate cells, which are the primary source for activated fibroblasts in liver, is involved in the fibrotic processes in nonalcoholic steatohepatitis. 30, 47 Therefore, miR-33 is considered as a profibrotic miR in pathological conditions.
Cardiac fibrosis is a characteristic of failing hearts. 5, 8, 15, 20 Our data are paradoxical, in that deficiency of miR-33 reduced systolic function after chronic pressure overload, despite ameliorated cardiac fibrosis. Recently, however, it has been said that CFs and fibrosis have both adaptive and maladaptive sides, and some reports showed inconsistency between cardiac fibrosis and hypertrophy (or LV function) in the remodeling heart. 5, 20, 21, 48 For example, it has been reported that deficiency of Smad3, which is essential for canonical TGF-β (transforming growth factor beta) signaling, showed increased heart weight and worsened heart failure after TAC, despite decreased cardiac fibrosis in mice. 48 Although persistent cardiac fibrosis is detrimental, fibroblasts also play a protective role in the heart by producing a necessary acute wound healing response. In addition, there are 2 types of cardiac fibrosis: reactive and reparative. 49 Reactive fibrosis in the early phase of remodeling is different from the reparative (replacement) fibrosis that follows cardiac myocyte death. In our data, proliferation of fibroblasts was impaired in vivo in the acute phase (1 week after TAC) in miR-33KO mice (and also in vitro), and fibrotic responses in the early phase (2-4 weeks) were suppressed without affecting cardiac myocyte hypertrophy, and LV function worsened in the chronic phase (8 weeks). Therefore, we can explain that impaired proliferation of fibroblasts in miR-33KO mice was primary, and it resulted in inadequate reactive fibrosis and insufficient adaptive responses, such as protective paracrine factors from CFs (Online Figure XIII) .
There may be additional cells that affect the phenotype of miR-33KO mice because the phenotype observed in FBKO mice was not so prominent as in systemic KO mice. Macrophages are also important for cardiac fibrosis and remodeling. Although the expression of Tgfb3 was suppressed in peritoneal macrophages in vitro, we did not detect significant differences in macrophage infiltration between WT and miR-33KO mice in vivo (Online Figure IV) .There are some reports that suggest miR-33 slows down the cell cycle by inhibiting the expression of genes associated with the cell cycle, such as CDK6 (cyclin-dependent kinase 6) and cyclin-D1. 52 We found that CDK6 was not increased in miR-33KO fibroblasts (Online Figure XI) . The result was probably because of the difference in cell types. Although CDK6 is preferentially expressed in hematopoietic cells, CDK4 is predominant over CDK6 in fibroblasts. 53 The importance of miRs in cardiac hypertrophy and fibrosis in pathological conditions has been demonstrated. [44] [45] [46] 54 Notably, with regard to fibroblasts, several miRs in CFs have been investigated intensively, including miR-21, miR-29, and miR-30. [55] [56] [57] [58] Interestingly, members of the miR-30 family are involved both in lipid metabolism and in cardiac fibrosis, 58, 59 like miR-33 in our data. These studies screened differentially expressing miRs in HF samples and in CFs. The changes of miR-33 expression in HF are not so prominent as these CFenriched miRs, probably because Srebf2 and miR-33 are ubiquitously expressed and cholesterol homeostasis is tightly regulated. The present study is notable, in that it showed the relationship between cellular lipid homeostasis and fibrotic responses.
Several limitations of this study should be acknowledged. There might be some variations in the quality of clinical biopsy samples. We did not use isolated cardiac myocytes from adult mice or human samples to analyze cell type-specific expression levels of miR-33, but instead used Percoll-isolated neonatal rat cardiac myocytes and fibroblasts because isolation of fresh cardiac myocytes from adult mice or human sample is technically difficult. To generate CF-specific KO mice, we used a Pn-Cre line, which express Cre recombinase only in a subset of fibroblasts in the heart, and there is still no truly specific marker of CFs.
Finally, inhibition of miR-33 is considered to be a potent therapeutic strategy for atherosclerosis because miR-33 has atherogenic effect by reducing HDL-C. 23, 41, 60 It is considered that inhibition of miR-33 results in altered cellular cholesterol content because of the target genes involved in cholesterol efflux and transfer, such as ABCA1, ABCG1, and NPC1. In our data, deficiency of miR-33 reduced the lipid raft cholesterol content in fibroblasts. Statins also reduce cellular cholesterol content, and they are reported to have pleiotropic effects on various diseases, such as prostate cancer, 61 Alzheimer disease, 62, 63 and HIV infection 64 through modulation of lipid rafts. 51 Therefore, our data implicated the possibility of pleiotropic effects of miR-33 inhibition. However, our data suggest that inhibition of miR-33 may cause cardiac dysfunction. It has also been reported that long-term silencing of miR-33 resulted in an unexpected increase in circulating triglyceride levels and lipid accumulation in the liver. 65 Because our genetic KO mice were equivalent to permanent inhibition, long-term inhibition of miR-33 can cause harmful side effects. To utilize the protective effect of miR-33 inhibition, further research is necessary.
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